Autoantibodies in Diabetes Mellitus: Current Utility and Perspectives

B. Isermann; R. Ritzel; M. Zorn; T. Schilling; P. P. Nawroth

doi:10.1055/s-2007-981452

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2007; 115(8): 483-490
DOI: 10.1055/s-2007-981452

Review

Autoantibodies in Diabetes Mellitus: Current Utility and Perspectives

B. Isermann¹ , R. Ritzel¹ , M. Zorn¹ , T. Schilling¹ , P. P. Nawroth¹

¹University of Heidelberg, Department of Internal Medicine I (Endocrinology) and Clinical Chemistry, Heidelberg, Germany

Abstract

Testing of autoantibodies in individuals at risk of developing or being newly diagnosed with diabetes mellitus is currently of very limited clinical value. However, clinical studies evaluating new therapeutic options for the delay or treatment of type 1 diabetes mellitus require sensitive, specific, and reliable assays for autoimmune antibodies associated with diabetes mellitus. With immune modulatory treatment of pre-diabetes mellitus on the horizon the need of reliable assays is evident. In addition, determination of autoimmune antibodies in diabetes mellitus facilitates studies investigating the pathophysiology underlying this disease. Clinicians and researchers should be aware of the tests available, their limitations, their clinical relevance, and their indications. This review focuses on the current knowledge about antibody assays for diabetes associated autoimmunity, their clinical value, their role in diagnosing and predicting autoimmune associated diabetes mellitus, and research applications.

Key words

Antibodies - autoimmunity, diabetes - autoimmunity - islet allografts - transplantation

Full Text

References

1 Assan R, Feutren G, Debray-Sachs M, Quiniou-Debrie MC, Laborie C, Thomas G, Chatenoud L, Bach JF. Metabolic and immunological effects of cyclosporin in recently diagnosed type diabetes mellitus. Lancet. 1985; 1 67-71
2 Schatz DA, Bingley PJ. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol Metab. 2001; 14 ((Suppl 1)) 619-622
3 Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet. 2001; 358 1749-1753
4 Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005; 352 2598-2608
5 Meziani F, Tesse A, David E, Martinez MC, Wangesteen R, Schneider F, Andriantsitohaina R. Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol. 2006; 169 1473-1483
6 Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986; 314 1360-1368
7 Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care. 2005; 28 1068-1076
8 Achenbach P, Bonifacio E, Ziegler AG. Predicting type 1 diabetes. Curr Diab Rep. 2005; 5 98-103
9 Wagner R, MacNally JM, Bonifacio E, Genovese S, Foulis A, MacGill M, Christie MR, Betterle C, Bosi E, Bottazzo GF. Lack of immunohistological changes in the islets of nondiabetic, autoimmune, polyendocrine patients with beta-selective GAD-specific islet cell antibodies. Diabetes. 1994; 43 851-856
10 Wagner R, Genovese S, Bosi E, Becker F, Bingley PJ, Bonifacio E, Miles KA, Christie MR, Bottazzo GF, Gale EA. Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia. 1994; 37 365-371
11 Powers AC, Bavik K, Tremble J, Daw K, Scherbaum WA, Banga JP. Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders. Clin Exp Immunol. 1999; 118 349-356
12 Genovese S, Bonifacio E, MacNally JM, Dean BM, Wagner R, Bosi E, Gale EA, Bottazzo GF. Distinct cytoplasmic islet cell antibodies with different risks for type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1992; 35 385-388
13 Devendra D, Franke B, Galloway TS, Horton SJ, Knip M, Wilkin TJ. Distinct idiotypes of insulin autoantibody in autoimmune polyendocrine syndrome type 2 and childhood onset type 1 diabetes. J Clin Endocrinol Metab. 2004; 89 5266-5270
14 Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab. 2003; 88 103-108
15 Wiest-Ladenburger U, Hartmann R, Hartmann U, Berling K, Bohm BO, Richter W. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes. 1997; 46 565-571
16 Hagopian WA, Michelsen B, Karlsen AE, Larsen F, Moody A, Grubin CE, Rowe R, Petersen J, MacEvoy R, Lernmark A. Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase. Diabetes. 1993; 42 631-636
17 Daw K, Powers AC. Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes. Diabetes. 1995; 44 216-220
18 Brooking H, Ananieva-Jordanova R, Arnold C, Amoroso M, Powell M, Betterle C, Zanchetta R, Furmaniak J, Smith BR. A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta. 2003; 331 55-59
19 Mziaut H, Trajkovski M, Kersting S, Ehninger A, Altkruger A, Lemaitre RP, Schmidt D, Saeger HD, Lee MS, Drechsel DN, Muller S, Solimena M. Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol. 2006; 8 435-445
20 Nan B, Yang H, Yan S, Lin PH, Lumsden AB, Yao Q, Chen C. C-reactive protein decreases expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Surgery. 2005; 138 212-222
21 Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJ, Bingley PJ, Bonifacio E, Ziegler AG. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004; 53 384-392
22 Bingley PJ, Gale EA. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia. 2006; 49 881-890
23 Ola TO, Biro PA, Hawa MI, Ludvigsson J, Locatelli M, Puglisi MA, Bottazzo GF, Fierabracci A. Importin beta: a novel autoantigen in human autoimmunity identified by screening random peptide libraries on phage. J Autoimmun. 2006; 26 197-207
24 Winer S, Tsui H, Lau A, Song A, Li X, Cheung RK, Sampson A, Afifiyan F, Elford A, Jackowski G, Becker DJ, Santamaria P, Ohashi P, Dosch HM. Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med. 2003; 9 198-205
25 Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, Paquette TL. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 1983; 222 1337-1339
26 Verge CF, Howard NJ, Rowley MJ, Mackay IR, Zimmet PZ, Egan M, Hulinska H, Hulinsky I, Silvestrini RA, Kamath S. Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: a population-based study. Diabetologia. 1994; 37 1113-1120
27 Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes. 1997; 46 1701-1710
28 Greenbaum CJ, Palmer JP, Kuglin B, Kolb H. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab. 1992; 74 1040-1044
29 Achenbach P, Ziegler AG. Diabetes-related antibodies in euglycemic subjects. Best Pract Res Clin Endocrinol Metab. 2005; 19 101-117
30 Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes. 2003; 52 1128-1136
31 Achenbach P, Schlosser M, Williams AJ, Yu L, Mueller PW, Bingley PJ, Bonifacio E. Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol. 2007; 122 85-90
32 Barker JM, Goehrig SH, Barriga K, Hoffman M, Slover R, Eisenbarth GS, Norris JM, Klingensmith GJ, Rewers M. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004; 27 1399-1404
33 Hummel M, Ziegler AG, Roth R. Psychological impact of childhood islet autoantibody testing in families participating in the BABYDIAB study. Diabet Med. 2004; 21 324-328
34 Carmichael B. The Human Genome Project-threat or promise?. J Intellect Disabil Res. 2003; 47 505-508
35 Fuchtenbusch M, Ferber K, Standl E, Ziegler AG. Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. Diabetes. 1997; 46 1459-1467
36 Lobner K, Knopff A, Baumgarten A, Mollenhauer U, Marienfeld S, Garrido-Franco M, Bonifacio E, Ziegler AG. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes. 2006; 55 792-797
37 Seissler J, Sonnaville JJ de, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, Lan MS, Notkins AL, Heine RJ, Scherbaum WA. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia. 1998; 41 891-897
38 Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997; 350 1288-1293
39 Falorni A, Brozzetti A. Diabetes-related antibodies in adult diabetic patients. Best Pract Res Clin Endocrinol Metab. 2005; 19 119-133
40 Kanungo A, Sanjeevi CB. IA-2 autoantibodies are predominant in latent autoimmune diabetes in adults patients from eastern India. Ann N Y Acad Sci. 2003; 1005 390-394
41 Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio F, Brunetti P, Sanjeevi CB, Falorni A. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf). 2000; 52 565-573
42 Bosi E, Braghi S, Maffi P, Scirpoli M, Bertuzzi F, Pozza G, Secchi A, Bonifacio E. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes. 2001; 50 2464-2471
43 Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006; 355 1318-1330
44 Kulmala P, Rahko J, Savola K, Vahasalo P, Veijola R, Sjoroos M, Reunanen A, Ilonen J, Knip M. Stability of autoantibodies and their relation to genetic and metabolic markers of Type I diabetes in initially unaffected schoolchildren. Diabetologia. 2000; 43 457-464
45 Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Palmer JP, Cuthbertson D, Eisenbarth GS, Krischer JP, Schatz D. Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. J Clin Endocrinol Metab. 2006; 91 1705-1713
46 Bingley PJ. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet cell antibody register users study. Diabetes. 1996; 45 1720-1728
47 Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care. 2007; 30 38-42
48 Stene LC, Thorsby PM, Berg JP, Ronningen KS, Undlien DE, Joner G. The relation between size at birth and risk of type 1 diabetes is not influenced by adjustment for the insulin gene (-23HphI) polymorphism or HLA-DQ genotype. Diabetologia. 2006; 49 2068-2073
49 Kulmala P, Savola K, Petersen JS, Vahasalo P, Karjalainen J, Lopponen T, Dyrberg T, Akerblom HK, Knip M. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The childhood diabetes in Finland study group. J Clin Invest. 1998; 101 327-336
50 Decochez K, De Leeuw IH, Keymeulen B, Mathieu C, Rottiers R, Weets I, Vandemeulebroucke E, Truyen I, Kaufman L, Schuit FC, Pipeleers DG, Gorus FK. IA-2 autoantibodies predict impending type I diabetes in siblings of patients. Diabetologia. 2002; 45 1658-1666
51 Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996; 45 926-933
52 Achenbach P, Warncke K, Reiter J, Williams AJ, Ziegler AG, Bingley PJ, Bonifacio E. Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives. Diabetologia. 2006; 49 2969-2976
53 Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes. 1999; 48 460-468
54 Hamalainen AM, Ronkainen MS, Akerblom HK, Knip M. Postnatal elimination of transplacentally acquired disease-associated antibodies in infants born to families with type 1 diabetes. The finnish TRIGR study group. Trial to reduce IDDM in the genetically at risk. J Clin Endocrinol Metab. 2000; 85 4249-4253
55 Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, Eisenbarth GS, Rewers M. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab. 2004; 89 3896-3902
56 Libman IM, Pietropaolo M, Trucco M, Dorman JS, Laporte RE, Becker D. Islet cell autoimmunity in white and black children and adolescents with IDDM. Diabetes Care. 1998; 21 1824-1827
57 Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest. 2004; 114 589-597
58 Mayr A, Schlosser M, Grober N, Kenk H, Ziegler AG, Bonifacio E, Achenbach P. GAD Autoantibody Affinity and Epitope Specificity Identify Distinct Immunization Profiles in Children at Risk for Type 1 Diabetes. Diabetes. 2007;
59 Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia. 2003; 46 305-321
60 Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes. 2006; 55 2588-2594
61 Koczwara K, Bonifacio E, Ziegler AG. Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes. Diabetes. 2004; 53 1-4
62 Greeley SA, Katsumata M, Yu L, Eisenbarth GS, Moore DJ, Goodarzi H, Barker CF, Naji A, Noorchashm H. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med. 2002; 8 399-402
63 Gianani R, Putnam A, Still T, Yu L, Miao D, Gill RG, Beilke J, Supon P, Valentine A, Iveson A, Dunn S, Eisenbarth GS, Hutton J, Gottlieb P, Wiseman A. Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab. 2006; 91 1855-1861
64 Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB, Cornelius JG. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat Med. 2000; 6 278-282
65 Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?. Diabetologia. 2005; 48 2221-2228
66 Vardi P, Ziegler AG, Mathews JH, Dib S, Keller RJ, Ricker AT, Wolfsdorf JI, Herskowitz RD, Rabizadeh A, Eisenbarth GS. Concentration of insulin autoantibodies at onset of type I diabetes. Inverse log-linear correlation with age. Diabetes Care. 1988; 11 736-739
67 Seissler J, Sonnaville JJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, Lan MS, Notkins AL, Heine RJ, Scherbaum WA. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia. 1998; 41 891-897
68 Hagopian WA, Michelsen B, Karlsen AE, Larsen F, Moody A, Grubin CE, Rowe R, Petersen J, MacEvoy R, Lernmark A. Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase. Diabetes. 1993; 42 631-636
69 Verge CF, Howard NJ, Rowley MJ, Mackay IR, Zimmet PZ, Egan M, Hulinska H, Hulinsky I, Silvestrini RA, Kamath S. Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: a population-based study. Diabetologia. 1994; 37 1113-1120
70 Bonifacio E, Genovese S, Braghi S, Bazzigaluppi E, Lampasona V, Bingley PJ, Rogge L, Pastore MR, Bognetti E, Bottazzo GF. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia. 1995; 38 816-822
71 Vandewalle CL, Falorni A, Svanholm S, Lernmark A, Pipeleers DG, Gorus FK. High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian diabetes registry. J Clin Endocrinol Metab. 1995; 80 846-851

Correspondence

B. IsermannMD

University of Heidelberg

Department of Internal Medicine I and Clinical Chemistry

INF 410

69120 Heidelberg

Germany

Phone: +49/6221/56 38 608

Fax: +49/6221/56 42 33

Email: berend.isermann@med.uni-heidelberg.de